Last week I reported that AstraZeneca (AZ) posted an ad for CRESTOR on its "AZ Health Connections" corporate blog (see "AstraZeneca's Timely CRESTOR Branded Blog Post: Did It Violate Its Own Policy?"). The post included the indication for CRESTOR and also the "Important Safety Information" (ISI) that is required by the FDA whenever a drug company talks about a brand and its approved indication.
Spots in JUPITER An FDA advisory committee will be addressing whether to expand the label indications for the cholesterol drug Crestor to include healthy individuals with NORMAL cholesterol levels. The data to support doing this com... Read Post
The statin drug Crestor, made by AstraZeneca, recently received an expanded label indication from the FDA to include patients with normal cholesterol levels. At the same time, new studies indicate that statins increase the risk of d... Read Post
It's unusual for a pharmaceutical company to mention a product by brand name on its corporate blog. But AstraZeneca (AZ) has done just that on its "AZ Health Connections" corporate blog. The majority of the post "New CDC data shows ... Read Post